Bionsight Enters R&D Collaboration Agreement with Astellas for First-in-Class Autoimmune Disorder Therapy
Bionsight has entered into a global R&D collaboration agreement with Astellas Pharma Inc. to develop a first-in-class therapy for autoimmune disorders targeting the innate immune pathway.
Read more →